Fig. 5

Skin-specific DNAm predictor as a tool to validate the senotherapeutic potential of different compounds. a DNAm age residuals of primary human dermal fibroblasts treated with OSKMLN reprogramming factors (GSE142439 data) and untreated control samples (Ctrl). b–d Primary human dermal fibroblasts derived from HGPS donor treated with ABT-263 (ABT) at 1.25 and 5 μM, as well as 100 nM of Rapamycin (Rapa) for 3 days. Untreated cells were considered as controls (Ctrl). b Predicted DNAm age using the new skin-specific molecular clock, c senescence-associated beta-galactosidase (SA-β-Gal) staining intensity per nuclei, and the number of ATRX foci/cell. d Relative gene expression of CDKN2A (P16) and IL6 measured by qRT-PCR compared to untreated samples using ANOVA and Bonferroni *p < 0.05; **p < 0 < 0.01; ***p < 0.001; ****p < 0.0001